Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
暂无分享，去创建一个
M. Donia | I. Svane | E. Høgdall | J. Johansen | P. Geertsen | J. Hasselby | I. Chen | C. Chamberlain | A. Draghi | D. Nielsen | S. Theile | T. Lorentzen | E. Wilken | A. Toxværd | K. Madsen | Agnete W P Jensen | A. Jensen